1-4 of 4
Jan Pinkas
Close
Sort by
Journal Articles

Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant

Kevin A. Goncalves, PhD, Sharon L. Hyzy, MS, Katelyn J. Hammond, BS, Patrick C. Falahee, PhD, Haley Howell, BS, BA, Jan Pinkas, PhD, Veit Schmelmer, PhD, Jonathan G. Hoggatt, PhD, David T. Scadden, MD, Steven M Devine, MD, John F. DiPersio, MD PhD, Will J. Savage, MDPhD, John C. Davis, Jr., MD MPH, MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-142804
Published: 2020
Journal Articles

IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models

Sharlene Adams, PhD, Alan Wilhelm, Lauren Harvey, MS, Chen Bai, Nicholas Yoder, PhD, Yelena Kovtun, PhD, Thomas Chittenden, PhD, Jan Pinkas, PhD
Journal: Blood
Blood (2016) 128 (22): 2832.
https://doi.org/10.1182/blood.V128.22.2832.2832
Published: 2016
Journal Articles

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

Jutta Deckert, Peter U. Park, Sharon Chicklas, Yong Yi, Min Li, Katharine C. Lai, Michele F. Mayo, Christina N. Carrigan, Hans K. Erickson, Jan Pinkas, Robert J. Lutz, Thomas Chittenden, John M. Lambert
Journal: Blood
Blood (2013) 122 (20): 3500–3510.
https://doi.org/10.1182/blood-2013-05-505685
Published: 2013
Journal Articles

Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies,

Jutta Deckert, Ph.D., Sharon Chicklas, Yong Yi, Min Li, Jan Pinkas, Ph. D., Thomas Chittenden, Ph.D., Robert J. Lutz, PhD, Peter U. Park, Ph.D.
Journal: Blood
Blood (2011) 118 (21): 3726.
https://doi.org/10.1182/blood.V118.21.3726.3726
Published: 2011